Don

Don

Offline Online

Top Challenges in Managing NSCLC

90 0 Non-Small Cell Lung Cancer
Play Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Date added (newest)

Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer

Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer

RWE in Older Patients with Acute Myeloid Malignancies

RWE in Older Patients with Acute Myeloid Malignancies

Role of Venetoclax in Treatment of MDS @YaleCancer

Role of Venetoclax in Treatment of MDS @YaleCancer

PRIMO Study Investigating Duvelisib in PTCL

PRIMO Study Investigating Duvelisib in PTCL

Novel Approaches in Development for the Treatment of PTCL

Novel Approaches in Development for the Treatment of PTCL

Studies in PTCL

Studies in PTCL

T-Cell Lymphoma Therapy

T-Cell Lymphoma Therapy

Treatment of Hodgkin’s Lymphoma

Treatment of Hodgkin’s Lymphoma

Zanubrutinib in MCL

Zanubrutinib in MCL

1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork

1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork

BTK Inhibitors in the Management of Lymphoma

BTK Inhibitors in the Management of Lymphoma

Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews

Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews

Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer

46 0 Hematologic Malignancies

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

RWE in Older Patients with Acute Myeloid Malignancies

48 0 Hematologic Malignancies

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world evidence (RWE) in older patients with acute myeloid malignancies.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Role of Venetoclax in Treatment of MDS @YaleCancer

36 0 Hematologic Malignancies

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer
elaborates on the role of venetoclax in treatment of myelodysplastic syndromes (MDS).

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

PRIMO Study Investigating Duvelisib in PTCL

50 0 Hematologic Malignancies

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, shares outcomes from the PRIMO study investigating duvelisib in peripheral T-cell lymphoma (PTCL).

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Novel Approaches in Development for the Treatment of PTCL

17 0 Hematologic Malignancies

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, tells us about some of the novel approaches in development for the treatment of peripheral T-cell lymphoma (PTCL).

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Studies in PTCL

35 0 Hematologic Malignancies

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, discusses the most impressive studies in the treatment of peripheral T-cell lymphoma (PTCL) presented at ASH 2019.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

T-Cell Lymphoma Therapy

15 0 Hematologic Malignancies

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Treatment of Hodgkin’s Lymphoma

38 0 Hematologic Malignancies

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Zanubrutinib in MCL

15 0 Hematologic Malignancies

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL).

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork

20 0 Hematologic Malignancies

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

BTK Inhibitors in the Management of Lymphoma

11 0 Hematologic Malignancies

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews

26 0 Hematologic Malignancies

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead to the FDA approval of zanubrutinib.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
My videos
Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer

Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.
46 Views
3 years Ago
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
RWE in Older Patients with Acute Myeloid Malignancies
RWE in Older Patients with Acute Myeloid Malignancies
48 Views
Role of Venetoclax in Treatment of MDS @YaleCancer
Role of Venetoclax in Treatment of MDS @YaleCancer
36 Views
PRIMO Study Investigating Duvelisib in PTCL
PRIMO Study Investigating Duvelisib in PTCL
50 Views
Novel Approaches in Development for the Treatment of PTCL
Novel Approaches in Development for the Treatment of PTCL
17 Views
Studies in PTCL
Studies in PTCL
35 Views
T-Cell Lymphoma Therapy
T-Cell Lymphoma Therapy
15 Views
Treatment of Hodgkin’s Lymphoma
Treatment of Hodgkin’s Lymphoma
38 Views
Zanubrutinib in MCL
Zanubrutinib in MCL
15 Views
1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork
1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork
20 Views
BTK Inhibitors in the Management of Lymphoma
BTK Inhibitors in the Management of Lymphoma
11 Views
Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews
Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews
26 Views
Front-Line and Relapsed Mantle Cell Lymphoma @MDAndersonNews
Front-Line and Relapsed Mantle Cell Lymphoma @MDAndersonNews
12 Views
ZUMA-2 Trial in Mantle Cell Lymphoma @MDAndersonNews
ZUMA-2 Trial in Mantle Cell Lymphoma @MDAndersonNews
17 Views
Treatment Algorithms in MM @LevineCancer
Treatment Algorithms in MM @LevineCancer
19 Views
Daratumumab Changing the way MM Patients are Treated Today
Daratumumab Changing the way MM Patients are Treated Today
27 Views
Phase 2 Griffin Study in Newly Diagnosed MM @LevineCancer
Phase 2 Griffin Study in Newly Diagnosed MM @LevineCancer
8 Views
Phase 3 ELEVATE TN Study in CLL @SeattleCCA
Phase 3 ELEVATE TN Study in CLL @SeattleCCA
41 Views
Zanubrutinib in RR-MC @SeattleCCA
Zanubrutinib in RR-MC @SeattleCCA
20 Views
Phase 2 CAPTIVATE Study in CLL @SeattleCCA
Phase 2 CAPTIVATE Study in CLL @SeattleCCA
24 Views
BTK Inhibitors in CLL @SeattleCCA
BTK Inhibitors in CLL @SeattleCCA
10 Views
Veneto-STOP Study @SeattleCCA
Veneto-STOP Study @SeattleCCA
31 Views
Patient Profile in MCL Most Suitable for Zanubrutinib
Patient Profile in MCL Most Suitable for Zanubrutinib
9 Views
Recent FDA Approval of Zanubrutinib
Recent FDA Approval of Zanubrutinib
17 Views
Reducing Toxicity of CAR-T Cel Therapy
Reducing Toxicity of CAR-T Cel Therapy
11 Views
Loading